FIMECS Presents at the 19th Annual Drug Discovery Chemistry

Kanagawa, Japan, 30th March 2024 – FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Shigeru Furukubo, Ph.D., Principal Scientist at FIMECS, will make a presentation at the 19th Annual Drug Discovery Chemistry (1st -4th April 2024 in San Diego, CA, USA). Title is "Exploring Suitable E3 Ligase Binders for Discovery of Targeted Protein Degraders by Phenotypic-First Approach". In this presentation, identification of degraders using novel E3 ligase binders by RaPPIDS™ platform technology with "Phenotypic-First Approach", which enables highly efficient synthesis and evaluation of multiple degraders, and their optimization for orally bioavailable degraders will be introduced.

For more information: https://www.drugdiscoverychemistry.com/

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company's proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com